Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women

Hypertension

Volumn 51, Issue 4 PART 2 SUPPL., 2008, Pages 1115-1122

  Wassertheil Smoller, Sylvia ^a   Kooperberg, Charles ^b   McGinn, Aileen P ^a   Kaplan, Robert C ^a   Hsia, Judith ^c   Hendrix, Susan L ^d   Manson, JoAnn E ^e   Berger, Jeffrey S ^f   Kuller, Lewis H ^g   Allison, Matthew A ^h   Baird, Alison E ⁱ  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c ASTRAZENECA   (United Kingdom)

^d WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^h UNIVERSITY OF CALIFORNIA   (United States)

ⁱ National Institute of Neurological Disorders   (United States)

Author keywords

Hormones; Lipoprotein associated phospholipase A2; Lp PLA 2; Postmenopausal women; Stroke; Stroke biomarkers; WHI; Women's Health Initiative

Indexed keywords

1 ALKYL 2 ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; ESTROGEN; GESTAGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; AGED; ANGINA PECTORIS; ARTICLE; BODY MASS; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; FEMALE; HEART ATRIUM FIBRILLATION; HORMONAL THERAPY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PRIORITY JOURNAL; RISK FACTOR; SYSTOLIC BLOOD PRESSURE;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; AGED; BIOLOGICAL MARKERS; BRAIN ISCHEMIA; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; ESTROGEN REPLACEMENT THERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RISK FACTORS; STROKE; WOMEN'S HEALTH;

EID: 40849124345     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.107.103721     Document Type: Article

References (20)

1. Hurt-Camejo E, Camejo G, Sartipy P. Phospholipase a2 and small, dense low-density lipoprotein. Curr Opin Lipidol. 2000;11:465-471.
2. Zalewski A, Macphee C. Role of lipoprotein-associated phospholipase a2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol. 2005;25:923-931.
3. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. Lipoprotein-associated phospholipase a2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol. 2006;26:2523-2529.
4. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. Lipoprotein-associated phospholipase a2, high-sensitivity c-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the atherosclerosis risk in communities (aric) study. Arch Intern Med. 2005;165:2479-2484.
5. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. Lipoprotein-associated phospholipase a2 as an independent predictor of coronary heart disease. West of Scotland coronary prevention study group. N Engl J Med. 2000;343:1148-1155.
6. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. Lipoprotein-associated phospholipase a2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation. 2005;111:570-575.
7. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. Lipoprotein-associated phospholipase a2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the prove it-timi 22 (pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction) trial. Circulation. 2006;113:1745-1752.
8. Persson M, Hedblad B, Nelson JJ, Berglund G. Elevated lp-pla2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27:1411-1416.
9. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. Lipoprotein-associated phospholipase a2 adds to risk prediction of incident coronary events by c-reactive protein in apparently healthy middle-aged men from the general population: Results from the 14-year follow-up of a large cohort from southern Germany. Circulation. 2004;110:1903-1908.
10. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase a2 and cardiovascular disease: a systematic review. Mayo Clin Proc. 2007;82:159-165.
11. Blake GJ, Dada N, Fox JC, Manson JE, Ridker PM. A prospective evaluation of lipoprotein-associated phospholipase a(2) levels and the risk of future cardiovascular events in women. J Am Coll Cardiol. 2001;38:1302-1306.
12. Hays J, Hunt JR, Hubbell FA, Anderson GL, Limacher M, Allen C, Rossouw JE. The Women's Health Initiative recruitment methods and results. Ann Epidemiol. 2003;13:S18-77.
13. Langer RD, White E, Lewis CE, Kotchen JM, Hendrix SL, Trevisan M. The Women's Health Initiative observational study: Baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol. 2003;13:S107-S121.
14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation. 2002;106:3143-3421.
15. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, Kotchen JM, Ockene J. Risks and benefits of estrogen plus progestin in healthy postmenopausal women, principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
16. Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner R, Brzyski R, Caan B, Chlebowski R, Curb D, Gass M, Hays J, Heiss G, Hendrix S, Howard BV, Hsia J, Hubbell A, Jackson R, Johnson KC, Judd H, Kotchen JM, Kuller L, LaCroix AZ, Lane D, Langer RD, Lasser N, Lewis CE, Manson J, Margolis K, Ockene J, O'Sullivan MJ, Phillips L, Prentice RL, Ritenbaugh C, Robbins J, Rossouw JE, Sarto G, Stefanick ML, Van Horn L, Wactawski-Wende J, Wallace R, Wassertheil-Smoller S. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA. 2004;291:1701-1712.
17. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Kooperberg C, Rossouw JE, Trevisan M, Aragaki A, Baird AE, Bray PF, Buring JE, Criqui MH, Herrington D, Lynch JK, Rapp SR, Torner J. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. Circulation. 2006;113:2425-2434.
18. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, Kotchen T, Curb JD, Black H, Rossouw JE, Aragaki A, Safford M, Stein E, Laowattana S, Mysiw WJ. Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA. 2003;289:2673-2684.
19. Ballantyne CM, Nambi V. Markers of inflammation and their clinical significance. Atherosclerosis. 2005;6(suppl):21-29.
20. Ballantyne C, Cushman M, Psaty B, Furberg C, Khaw KT, Sandhu M, Oldgren J, Rossi GP, Maiolino G, Cesari M, Lenzini L, James SK, Rimm E, Collins R, Anderson J, Koenig W, Brenner H, Rothenbacher D, Berglund G, Persson M, Berger P, Brilakis E, McConnell JP, Sacco R, Elkind M, Talmud P, Cannon CP, Packard C, Barrett-Connor E, Hofman A, Kardys I, Witteman JC, Criqui M, Corsetti JP, Rainwater DL, Moss AJ, Robins S, Bloomfield H, Collins D, Wassertheil-Smoller S, Ridker P, Danesh J, Gu D, Nelson JJ, Thompson S, Zalewski A, Zariffa N, Di Angelantonio E, Kaptoge S, Thompson A, Walker M, Watson S, Wood A. Collaborative meta-analysis of individual participant data from observational studies of lp-pla2 and cardiovascular diseases. Eur J Cardiovasc Prev Rehabil. 2007;14:3-11.